Submissions for variant NM_170707.4(LMNA):c.1621C>T (p.Arg541Cys)

dbSNP: rs56984562

Total submissions: 10

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000211786	SCV000065018	pathogenic	Primary dilated cardiomyopathy	2018-04-06	criteria provided, single submitter	clinical testing	The p.Arg541Cys variant in LMNA has been identified in 6 individuals with DCM (F orissier 2003, Muchir 2004, Saj 2009, LMM data) and in one individual with sudde n cardiac death (Hookana 2008), occurring de novo in 2 cases (paternity confirme d). It was also shown to segregate with disease in 5 affected relatives from 4 f amilies (Forissier 2003, Hookana 2008, LMM data). It was absent from large popul ation studies. This variant has been shown to cause nuclear lamina abnormalities (Muchir 2004). Computational prediction tools and conservation analysis suggest that this variant may impact the protein and additional variants involving this amino acid, p.Arg541Ser and p.Arg541His, have been associated with DCM. In summ ary, this variant meets our criteria to be classified as pathogenic based upon c ase observations, de novo occurrences, segregation studies, absence from control s, and functional evidence. ACMG/AMP Criteria applied: PM6_Strong; PM2; PM5; PS4 _Moderate; PP1_Moderate; PP3.
Eurofins Ntd Llc (ga)	RCV000057343	SCV000224965	pathogenic	not provided	2014-12-16	criteria provided, single submitter	clinical testing
GeneDx	RCV000057343	SCV000234708	pathogenic	not provided	2022-04-14	criteria provided, single submitter	clinical testing	Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies examined the effect of p.(R541C) on the nuclear envelope in cultured skin fibroblasts and reported an absence or significant decrease in lamin B1 expression, as well as a lobulated nuclear envelope, in comparison to controls (Muchir et al., 2004); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 18031519, 31912959, 30847666, 24375749, 24503780, 19167105, 24623722, 19933576, 23702046, 27532257, 15724423, 22464770, 30165862, 29952368, 31383942, 32458740, 31447099, 32914734, 30975432, 33250842, 14675861, 10939567, 15372542)
Athena Diagnostics Inc	RCV000041325	SCV000255784	pathogenic	Dilated cardiomyopathy 1A	2015-08-27	criteria provided, single submitter	clinical testing
Ambry Genetics	RCV000242991	SCV000320572	pathogenic	Cardiovascular phenotype	2022-06-01	criteria provided, single submitter	clinical testing	The p.R541C pathogenic mutation (also known as c.1621C>T), located in coding exon 10 of the LMNA gene, results from a C to T substitution at nucleotide position 1621. The arginine at codon 541 is replaced by cysteine, an amino acid with highly dissimilar properties. This mutation was reported in a Moroccan family with dilated cardiomyopathy (DCM), and co-segregation was observed in several affected family members (Adadi N et al. Anatol J Cardiol, 2018 Jul;20:65-68). This mutation has been associated with severe ventricular arrhythmia, left ventricular wall motion abnormalities, dilated cardiomyopathy (DCM) with significant left ventricular segmental contractility defects, and sudden cardiac death (Forissier JF et al. Eur. J. Heart Fail., 2003 Dec;5:821-5; Hookana E et al. J. Cardiovasc. Electrophysiol., 2008 Jul;19:743-7; Saj M et al. Int. J. Cardiol., 2010 Oct;144:e51-3). The mutation was shown to be associated with abnormal nuclear envelop folding in two independent studies (Muchir A et al. Muscle Nerve, 2004 Oct;30:444-50; Hookana E et al, 2008). Additionally, alterations at the same amino acid position, p.R541S (Sylvius N et al. J. Med. Genet., 2005 Aug;42:639-47), p.R541G (Maek LA et al. J. Hum. Genet., 2011 Jan;56:83-6), p.R541P (van Tintelen JP et al. Am. Heart J., 2007 Dec;154:1130-9), and p.R541H (Rudenskaya GE et al. Clin. Genet., 2008 Aug;74:127-33) have also been reported in families with cardiomyopathy. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Invitae	RCV000462793	SCV000548875	pathogenic	Charcot-Marie-Tooth disease type 2	2023-12-09	criteria provided, single submitter	clinical testing	This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 541 of the LMNA protein (p.Arg541Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with cardiac arrest and left ventricular fibrosis and dilated cardiomyopathy (PMID: 14675861, 15724423, 18031519, 22464770, 24503780, 27532257). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 48046). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LMNA protein function with a positive predictive value of 95%. This variant disrupts the p.Arg541 amino acid residue in LMNA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22186027, 24623722). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
SIB Swiss Institute of Bioinformatics	RCV000041325	SCV000803622	likely pathogenic	Dilated cardiomyopathy 1A	2018-05-31	criteria provided, single submitter	curation	This variant is interpreted as a Likely Pathogenic, for Dilated cardiomyopathy, in Autosomal Dominant manner. The following ACMG Tag(s) were applied: PP3 => Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PM1 => Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation (PMID:18035086,16061563,18564364,21085127). PS3 => Well-established functional studies show a deleterious effect (PMID:15372542).
CeGaT Center for Human Genetics Tuebingen	RCV000057343	SCV003916513	pathogenic	not provided	2023-02-01	criteria provided, single submitter	clinical testing	LMNA: PM2, PM5, PP1:Moderate, PS4:Moderate, PP4, PS3:Supporting
Epithelial Biology; Institute of Medical Biology, Singapore	RCV000057343	SCV000088456	not provided	not provided		no assertion provided	not provided
Stanford Center for Inherited Cardiovascular Disease, Stanford University	RCV000057343	SCV000925146	pathogenic	not provided	2016-06-06	no assertion criteria provided	provider interpretation	We consider this variant to be very likely pathogenic and we do feel it is suitable for assessing risk in healthy relatives ("predictive genetic testing"). The reasons for this classification include strong case data, including de novo occurrence and some segregation data in two families; functional studies supporting pathogenicity; and multiple other reported disease causing variants affecting the same codon. We have seen this variant in a patient with DCM. Testing was performed by Invitae. The variant has been seen in at least 6 unrelated cases of dilated cardiomyopathy and/or arrhythmia (not including this patient's family). Forissier J et al., 2003 reported the R541C variant in a father and daughter with DCM and arrhythmias. R541C occurred de novo in the father in the context of a negative family history in preceding generations. Muchir et al., 2004 reported to be a 29 year-old with DCM and conduction system disease. They performed functional studied in cultured skin fibroblasts and reported an absence or significant decrease in lamin B1 expression and a lobulated nuclear envelope with the R541C variant compared to controls. Hookana et al., 2008 reported the R541C variant in a mother with a history of an aborted SCD and LV hypokinesia and thinning and daughter who died suddenly and was found to have localize LV thinning and fibrosis. The variant was found to have occurred de novo in the mother in the context of a negative family history. Saj M et al., 2010 reported a 19 year old with LV DCM s/p ICD implantation and aborted VFib cardiac arrests, with a family history of SCD. Pugh et al., 2014 reported R541C in two individuals with DCM, one of which also carried a mutation in the LDB3 gene, per the LMM ClinVar entry. Other variants at the same codon (R541H, R541G, R541P, R541S) have been reported in association with dilated cardiomyopathy and other laminopathies, supporting the hypothesis that this codon occurs at a functionally important location in the protein. Per the Invitae report, "This sequence change replaces arginine with cysteine at codon 541 of the LMNA protein (p.Arg541Cys). The arginine residue is highly conserved and there is a large physicochemical difference between arginine and cysteine." Please note that the average coverage at this site in ExAC is poor: The mean depth is ~16x, the median depth is 4x, and ~95% of people have ~1x coverage, with ~40% having 5x coverage. The variant was reported online in 2 of 10,695 individuals in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/), which currently includes variant calls on ~64,000 individuals of European, African, Latino and Asian descent (as of 6/6/2016). Specifically, the variant was observed in 2 of 4,568 non-Finnish European people. The phenotype of those individuals is not publicly available. The dataset is comprised of multiple cohorts, some of which were recruited from the general population, others were enriched for common cardiovascular disease.